Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix-IPV Booster Co-administered with MMR in Children
NCT00263692Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2002
- Primary completion
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus vaccine in diphtheria, Tetanus, pertussis and 1 more (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity after vaccination. Started Nov 2002; status: completed.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT00263692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263692.